Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-Resistant Primary Peritoneal Carcinoma”

109 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 109 results

Testing effectiveness (Phase 2)Study completedNCT01402271
What this trial is testing

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
European Organisation for Research and Treatment of Cancer - EORTC 88
Testing effectiveness (Phase 2)UnknownNCT04375956
What this trial is testing

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Study completedNCT03026062
What this trial is testing

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Study completedNCT00461786
What this trial is testing

Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPeritoneal Cancer
Eli Lilly and Company 51
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00993616
What this trial is testing

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+7 more
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Study completedNCT00004081
What this trial is testing

Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPeritoneal Cavity Cancer
Beth Israel Deaconess Medical Center 30
Testing effectiveness (Phase 2)WithdrawnNCT02948101
What this trial is testing

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center
Early research (Phase 1)Active Not RecruitingNCT01883297
What this trial is testing

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
RecurrentPlatinum-resistantHigh Grade Serous Ovarian Cancer+2 more
University Health Network, Toronto 3
Large-scale testing (Phase 3)Study completedNCT01204749
What this trial is testing

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 919
Early research (Phase 1)Active Not RecruitingNCT05691504
What this trial is testing

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Who this might be right for
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube Carcinoma+8 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Ended earlyNCT00084448
What this trial is testing

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Large-scale testing (Phase 3)WithdrawnNCT03632798
What this trial is testing

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
Cordgenics, LLC
Large-scale testing (Phase 3)Looking for participantsNCT05281471
What this trial is testing

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more
Genelux Corporation 186
Not applicableUnknownNCT01372787
What this trial is testing

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
AnxietyFatigueNausea and Vomiting+20 more
Gynecologic Oncology Group 103
Testing effectiveness (Phase 2)Study completedNCT00888615
What this trial is testing

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+15 more
GOG Foundation 58
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Testing effectiveness (Phase 2)Study completedNCT00005836
What this trial is testing

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT02440425
What this trial is testing

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute 42
Next Page